---
title: "MicroPort MedBot Proposes New Share Scheme to Replace Existing Incentive Plans"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286423581.md"
description: "Shanghai MicroPort MedBot (Group) Co., Ltd. plans to implement a new share scheme to replace its existing incentive plans, allowing the granting of new and existing shares and options to eligible participants. This initiative aims to enhance alignment with key stakeholders and support talent retention. The current schemes will be terminated upon approval from shareholders and the Hong Kong listing committee. No shares have been granted under the existing plans. The latest analyst rating for the stock (HK:2252) is a Buy with a price target of HK$45.00."
datetime: "2026-05-14T13:12:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286423581.md)
  - [en](https://longbridge.com/en/news/286423581.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286423581.md)
---

# MicroPort MedBot Proposes New Share Scheme to Replace Existing Incentive Plans

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) has shared an update.

Shanghai MicroPort MedBot (Group) Co., Ltd. plans to adopt a new share scheme that will allow the company to grant new and existing shares, as well as options over new shares, to eligible participants as incentives for their contributions or potential contributions. The initiative is intended to enhance long-term alignment between the company and key stakeholders, supporting talent retention and motivation across the group.

The proposed scheme will replace the company’s existing share award and share option schemes, which will be terminated once the new framework is approved by shareholders and the Hong Kong listing committee. No shares or options have been granted under the existing schemes to date, and a circular outlining the key terms of the new scheme will be sent to shareholders ahead of the general meeting where the proposal will be considered.

The most recent analyst rating on (HK:2252) stock is a Buy with a HK$45.00 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.

**More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H**

Shanghai MicroPort MedBot (Group) Co., Ltd. is a mainland China-based medical technology company focused on surgical robotics and related innovative medical devices. Listed in Hong Kong under stock code 2252, the group operates through subsidiaries to develop and commercialize advanced solutions for minimally invasive and precision surgery in domestic and international markets.

**Average Trading Volume:** 6,168,906

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$28.73B

### Related Stocks

- [02252.HK](https://longbridge.com/en/quote/02252.HK.md)

## Related News & Research

- [MicroPort MedBot Sets 2026 AGM With New Capital Mandates on the Table](https://longbridge.com/en/news/286426445.md)
- [Figure AI had one of its robots race a human to sort packages. It lost.](https://longbridge.com/en/news/286883540.md)
- [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md)
- [ElliQ is a surprisingly helpful companion robot for older adults](https://longbridge.com/en/news/286673621.md)
- [Unitree Robotics and DEEP Robotics Accelerate IPO Progress; Shoucheng Holdings' Robotics Investments Enter a Value Validation Phase](https://longbridge.com/en/news/286853966.md)